Related references
Note: Only part of the references are listed.Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma
Julie A. Ellerhorst et al.
CLINICAL CANCER RESEARCH (2011)
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma
Evan M. Hersh et al.
INVESTIGATIONAL NEW DRUGS (2011)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
Paul B. Chapman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
S. J. O'Day et al.
ANNALS OF ONCOLOGY (2010)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Jedd D. Wolchok et al.
LANCET ONCOLOGY (2010)
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
Georgia Hatzivassiliou et al.
NATURE (2010)
Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma
Sanjiv S. Agarwala
MELANOMA RESEARCH (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Immunotherapy of distant metastatic disease
D. Schadendorf et al.
ANNALS OF ONCOLOGY (2009)
Small molecules and targeted therapies in distant metastatic disease
P. Hersey et al.
ANNALS OF ONCOLOGY (2009)
Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters
Lotte Engell-Noerregaard et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Ipilimumab: controversies in its development, utility and autoimmune adverse events
Jeffrey Weber
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
Jeffrey Weber et al.
CLINICAL CANCER RESEARCH (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Current systemic therapy for metastatic melanoma
Sanjiv S. Agarwala
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Phase I/II Trial of Tremelimumab in Patients With Metastatic Melanoma
Luis H. Camacho et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
Axel Hauschild et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Final Version of 2009 AJCC Melanoma Staging and Classification
Charles M. Balch et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Current management of metastatic melanoma
Van Anh Trinh
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2008)
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
A. Ribas et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Anti-Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
Lawrence Fong et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
R. Dummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Overcoming Immunologic Tolerance to Melanoma: Targeting CTLA-4 with Tremelimumab (CP-675,206)
Antoni Ribas
ONCOLOGIST (2008)
The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation
Jedd D. Wolchok et al.
ONCOLOGIST (2008)
Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity
James Tsai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) - A novel strategy for the treatment of melanoma and other malignancies
Steven J. O'Day et al.
CANCER (2007)
Treatments for metastatic melanoma: Synthesis of evidence from randomized trials
Philip Lui et al.
CANCER TREATMENT REVIEWS (2007)
Targeting immunosupportive cancer therapies: Accentuate the positive, eliminate the negative
Karl S. Peggs et al.
CANCER CELL (2007)
Single-agent interleukin-2 in the treatment of metastatic melanoma: A systematic review
Teresa Petrella et al.
CANCER TREATMENT REVIEWS (2007)
Review: Anti-CTLA-4 antibody ipilimumab: Case studies of clinical response and immune-related adverse events
Jeffrey Weber
ONCOLOGIST (2007)
Toward a molecular classification of melanoma
Leslie A. Fecher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Costimulation, coinhibition and cancer
Brant A. Inman et al.
CURRENT CANCER DRUG TARGETS (2007)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients
Ruggero Ridolfi et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2006)
Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
Kimberly E. Beck et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study
AV Maker et al.
ANNALS OF SURGICAL ONCOLOGY (2005)
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4
P Attia et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Medical progress - Management of cutaneous melanoma
H Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
MR Middleton et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)